Laying the Foundation for Personalized Smoking Cessation Treatment in the American Indian Population

摘要 这项建议的总体目标是提供培训、职业发展和指导，从而 在候选人中，卡罗尔博士有能力开发一个独立的研究项目，带来基因研究 为美国印第安人和阿拉斯加提供商业戒烟治疗的个性化方法 原生(人工智能/人工智能)人口。卡罗尔博士是明尼苏达大学(UMN)商学院的助理教授 公共卫生与共济会癌症中心的预约。卡罗尔博士完成了研究生培训 流行病学和公共卫生，以及分子遗传学的本科培训。她完成了两年的学业。 在NIH T32的支持下，UMN烟草研究项目的博士后奖学金获得 临床试验方面的专业知识。在这个职业发展奖的五年里，卡罗尔博士计划发展 在吸烟行为的遗传因素、遗传数据的统计分析和定性数据方面的专业知识 在人工智能/人工智能中理解基因研究障碍的技能。这些新的培训领域对于 候选人能够全面服务于希望开展基于基因的研究和 戒烟方法。候选人拥有一支强大的指导团队，其中包括世界知名的 学术科学家和与AI/AN社区的联系，以及相关的职业发展计划 使她发展成为一名成功的学术研究人员，并通过 R01授予机制。研究提案的基础是与一个人工智能部落的现有合作 商业吸烟率高达60%。Aim i的目标是检测尼古丁代谢基因。 以及表型数据，这为优化戒烟治疗提供了证据，并与 人工智能吸烟者的尼古丁剂量和吸烟强度，以及尼古丁依赖。申请者还将 探索吸烟行为的社会和文化决定因素，因此有可能提供 全面了解为什么人工智能吸烟率如此之高，戒烟成功率很低。AIM II利用焦点 评估对参与基因研究和遗传信息了解的看法和障碍的团体 戒烟治疗的方法和克服人工智能吸烟者及其医疗保健障碍的方法 供应商。AIM III的目标是扩大候选人与AI Tribe的现有合作，以便 候选人可以帮助更多的部落制定有效的戒烟干预措施。最终，完成 这项研究将提供证据，证明卡罗尔博士在与人工智能部落合作方面的专业知识， 可行的基因研究，并将使她能够进行更多的基因研究和遗传信息 有高吸烟史和低吸烟率人群的戒烟治疗方法 参与基因研究。这项提议和对卡罗尔博士的投资的结果继续 培训有可能极大地减少AI/AN人群中的商业香烟吸烟。

ABSTRACT The overall goal of this proposal is to provide the training, career development, and mentorship that will result in the candidate Dr. Carroll’s ability to develop an independent program of research that brings genetic studies and personalized approaches to commercial smoking cessation treatment to the American Indian and Alaska Native (AI/AN) population. Dr. Carroll is an Assistant Professor at the University of Minnesota (UMN) School of Public Health with an appointment at the Masonic Cancer Center. Dr. Carroll completed graduate training in epidemiology and public health, and undergraduate training in molecular genetics. She completed a two year postdoctoral fellowship with the UMN Tobacco Research Programs with the support of an NIH T32 gaining expertise in clinical trials. During the five years of this career development award, Dr. Carroll plans to develop expertise in genetic contributors to smoking behavior, statistical analysis of genetic data, and qualitative data skills for understanding barriers to genetic research in AI/AN. These areas of new training are essential for the candidate to be able to fully serve Tribal communities who wish to embark upon genetic-based research and approaches to smoking cessation. The candidate has a strong mentorship team that includes world-renowned academic scientists and liaisons with the AI/AN community, and a relevant career development plan that will enable her to develop into a successful academic investigator and compete for independent funding through R01 grant mechanisms. The foundation of the research proposal is an existing collaboration with an AI Tribe with a commercial smoking prevalence >60%. The goal of Aim I is to examine nicotine metabolism genotype and phenotype data, which has evidence for optimizing cessation treatment, and relating to biomarkers of nicotine dose and smoking intensity, and nicotine dependence among AI smokers. The applicant will also explore social and cultural determinants of smoking behavior and therefore has the potential to provide a comprehensive picture for why AI smoke at such high rates and have poor quit success. Aim II utilizes focus groups to assess perceptions of and barriers to participating in genetic studies and genetically-informed approaches to cessation treatment and ways to overcome barriers among AI smokers and their healthcare providers. The goal of AIM III is to expand the candidate’s existing collaborations with AI Tribes so that the candidate can assist more Tribes in developing effective cessation interventions. Ultimately, the completion of this study will provide evidence of Dr. Carroll’s expertise in collaborating with AI tribes on a focused and highly feasible genetic study and will allow for her to pursue additional genetic studies and genetically-informed approaches to smoking cessation treatment in a population with a history of high smoking and low rates of participating in genetic research. The result of this proposal and investment in the Dr. Carroll’s continued training have the potential to dramatically reduce commercial cigarette smoking among the AI/AN population.